Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Alimera Sciences

Nasdaq:ALIM
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALIM
Nasdaq
$17M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • Alimera Sciences has significant price volatility in the past 3 months.
ALIM Share Price and Events
7 Day Returns
-21.6%
NasdaqGM:ALIM
4.1%
US Pharmaceuticals
-4.1%
US Market
1 Year Returns
-76.6%
NasdaqGM:ALIM
-7%
US Pharmaceuticals
-14.9%
US Market
ALIM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alimera Sciences (ALIM) -21.6% -46.6% -54.7% -76.6% -84.1% -95.1%
US Pharmaceuticals 4.1% -8.7% -12.1% -7% 4.7% 0.6%
US Market -4.1% -19.1% -23.4% -14.9% 3.5% 14.5%
1 Year Return vs Industry and Market
  • ALIM underperformed the Pharmaceuticals industry which returned -7% over the past year.
  • ALIM underperformed the Market in United States of America which returned -14.9% over the past year.
Price Volatility
ALIM
Industry
5yr Volatility vs Market

ALIM Value

 Is Alimera Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Alimera Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Alimera Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Alimera Sciences. This is due to cash flow or dividend data being unavailable. The share price is $3.44.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alimera Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alimera Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ALIM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.19
NasdaqGM:ALIM Share Price ** NasdaqGM (2020-04-02) in USD $3.44
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 19.88x
United States of America Market PE Ratio Median Figure of 2,944 Publicly-Listed Companies 12.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alimera Sciences.

NasdaqGM:ALIM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ALIM Share Price ÷ EPS (both in USD)

= 3.44 ÷ -2.19

-1.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alimera Sciences is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Alimera Sciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Alimera Sciences's expected growth come at a high price?
Raw Data
NasdaqGM:ALIM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.57x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
93.9%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.88x
United States of America Market PEG Ratio Median Figure of 2,008 Publicly-Listed Companies 0.91x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alimera Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alimera Sciences's assets?
Raw Data
NasdaqGM:ALIM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-7.01
NasdaqGM:ALIM Share Price * NasdaqGM (2020-04-02) in USD $3.44
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 2.41x
United States of America Market PB Ratio Median Figure of 5,142 Publicly-Listed Companies 1.22x
NasdaqGM:ALIM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ALIM Share Price ÷ Book Value per Share (both in USD)

= 3.44 ÷ -7.01

-0.49x

* Primary Listing of Alimera Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alimera Sciences has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.

Next steps:

  1. Take a look at Alimera Sciences's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Alimera Sciences's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Pharmaceuticals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Alimera Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Alimera Sciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ALIM Future Performance

 How is Alimera Sciences expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
93.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alimera Sciences expected to grow at an attractive rate?
  • Alimera Sciences's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Alimera Sciences's earnings growth is expected to exceed the United States of America market average.
  • Alimera Sciences's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ALIM Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ALIM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 93.9%
NasdaqGM:ALIM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 13.9%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ALIM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ALIM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 82 8 1
2021-12-31 73 2 3
2020-12-31 61 -6 5
2020-04-03
NasdaqGM:ALIM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 54 -4 -10
2019-09-30 52 -4 -12
2019-06-30 50 -4 21
2019-03-31 50 -6 22
2018-12-31 47 -12 17
2018-09-30 41 -14 11
2018-06-30 39 -14 -22
2018-03-31 39 -14 -23
2017-12-31 36 -13 -22
2017-09-30 37 -14 -21
2017-06-30 36 -18 -25
2017-03-31 35 -23 -29

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Alimera Sciences's earnings are expected to grow significantly at over 20% yearly.
  • Alimera Sciences's revenue is expected to grow by 13.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ALIM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Alimera Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ALIM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 1.22 1.22 1.22 1.00
2021-12-31 0.33 0.71 -0.06 2.00
2020-12-31 -1.17 -0.82 -1.64 4.00
2020-04-03
NasdaqGM:ALIM Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.19
2019-09-30 -2.55
2019-06-30 4.54
2019-03-31 4.78
2018-12-31 3.74
2018-09-30 2.43
2018-06-30 -4.70
2018-03-31 -5.04
2017-12-31 -4.93
2017-09-30 -4.71
2017-06-30 -5.88
2017-03-31 -7.47

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Alimera Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Alimera Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alimera Sciences has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ALIM Past Performance

  How has Alimera Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alimera Sciences's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alimera Sciences does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Alimera Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alimera Sciences's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Alimera Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alimera Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ALIM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 53.94 -10.44 38.96 10.99
2019-09-30 52.08 -12.02 38.18 11.20
2019-06-30 50.37 21.34 37.38 11.24
2019-03-31 50.23 22.38 36.92 11.18
2018-12-31 46.60 17.46 37.42 11.27
2018-09-30 40.63 11.31 37.99 11.47
2018-06-30 39.27 -21.74 38.39 11.24
2018-03-31 38.92 -22.95 37.31 10.71
2017-12-31 35.91 -22.00 36.25 9.99
2017-09-30 37.45 -20.70 37.70 9.81
2017-06-30 35.96 -24.66 39.48 10.50
2017-03-31 35.15 -28.76 42.96 11.47
2016-12-31 34.33 -33.17 44.69 12.38
2016-09-30 29.48 -37.96 43.96 13.10
2016-06-30 28.08 -30.26 42.84 13.92
2016-03-31 24.30 -32.00 42.04 14.53
2015-12-31 22.44 -30.65 42.28 14.84
2015-09-30 18.36 -29.94 40.53 14.19
2015-06-30 13.86 -35.41 36.98 14.26
2015-03-31 10.28 -25.69 32.03 12.39
2014-12-31 8.42 -36.66 27.46 11.81
2014-09-30 7.62 -41.43 24.12 11.29
2014-06-30 5.97 -35.53 25.46 8.92
2014-03-31 3.96 -57.95 26.32 9.16
2013-12-31 1.87 -51.18 23.82 8.86
2013-09-30 0.94 -41.70 26.05 8.28
2013-06-30 0.18 -45.98 21.28 8.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alimera Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Alimera Sciences has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alimera Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alimera Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alimera Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ALIM Health

 How is Alimera Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alimera Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alimera Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alimera Sciences's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Alimera Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Alimera Sciences has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alimera Sciences Company Filings, last reported 3 months ago.

NasdaqGM:ALIM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -4.45 38.66 9.43
2019-09-30 -6.48 38.50 7.90
2019-06-30 -3.68 38.29 12.16
2019-03-31 0.65 38.08 13.09
2018-12-31 2.72 37.87 13.04
2018-09-30 2.97 37.66 12.59
2018-06-30 5.54 37.46 16.69
2018-03-31 8.55 37.25 20.25
2017-12-31 14.92 34.37 24.07
2017-09-30 20.76 34.02 25.62
2017-06-30 21.70 33.69 26.88
2017-03-31 20.07 33.41 26.74
2016-12-31 25.59 33.08 30.98
2016-09-30 30.03 33.43 33.85
2016-06-30 11.80 33.81 16.63
2016-03-31 16.89 33.63 23.94
2015-12-31 26.32 31.79 31.08
2015-09-30 33.36 34.45 39.34
2015-06-30 33.33 34.36 48.14
2015-03-31 40.57 34.28 61.33
2014-12-31 49.52 33.33 76.70
2014-09-30 8.22 33.94 61.42
2014-06-30 13.66 9.31 41.99
2014-03-31 10.65 4.45 41.33
2013-12-31 -4.93 4.86 12.63
2013-09-30 9.20 5.00 23.10
2013-06-30 9.97 5.00 31.93
  • Alimera Sciences has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Alimera Sciences's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Alimera Sciences has sufficient cash runway for 2.2 years based on current free cash flow.
  • Alimera Sciences has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of -29.6% each year.
X
Financial health checks
We assess Alimera Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alimera Sciences has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ALIM Dividends

 What is Alimera Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alimera Sciences dividends.
If you bought $2,000 of Alimera Sciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alimera Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alimera Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ALIM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1941 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ALIM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alimera Sciences has not reported any payouts.
  • Unable to verify if Alimera Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alimera Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alimera Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Alimera Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alimera Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alimera Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ALIM Management

 What is the CEO of Alimera Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rick Eiswirth
COMPENSATION $831,292
AGE 51
TENURE AS CEO 1.3 years
CEO Bio

Mr. Richard S. Eiswirth, Jr., also known as Rick, has been President of Alimera Sciences, Inc. since January 1, 2016 and its Chief Executive Officer and Director since January 2, 2019. He was Chief Financial Officer at Alimera Sciences, Inc. since January 2016 until January 2, 2019 and again since October 2005 until August 2010. Mr. Eiswirth has been President and Chief Financial Officer at Alimera Sciences Limited since January 2016. Mr. Eiswirth served as the Chief Operating Officer of Alimera Sciences, Inc. from August 2010 to December 2015 and served as its Principal Accounting Officer, Treasurer, Secretary and Vice President. He was responsible for strategic finance, accounting, distribution, logistics, human resources and information technology. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. He has a wealth of financial management experience to the team with both public and private ventures. Since joining Alimera, he led Alimera Sciences's financing activities, raising over $300 million in private and public equity and debt financing. He joined Alimera Sciences in 2005. He has been active in Atlanta’s business circle for more than 20 years, with experience that includes financial and accounting management, mergers and acquisitions and initial public offerings, as well as entrepreneurial and start up operational activities. He was the founder of two consulting practices, Brand Ignition Group and Black River Holdings, Inc. in 2002. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc. He served as Senior Executive Vice President and Chief Financial Officer of Netzee Inc., a publicly owned affiliate of Intercept Group from August 1999 to April 2002. He served as Secretary of Netzee Inc. from August 1999 to 2002. He was responsible for the initial public offering and the identification, evaluation and negotiation of ten acquisitions that fortified Netzee's product offerings. He has extensive experience in managing investment bankers, brokers, attorneys and accountants. In this capacity, he provided audit, accounting, due diligence, merger and acquisition and consulting services to a variety of industries including real estate, technology, banking, insurance and financial services. Since April 2002, he has been involved in capital raising efforts for several start up technology services. He started his career in Arthur Andersen’s audit and business advisory practice where he was a senior manager and certified public accountant from 1991 to 1999. He served as the Chairman of Jones Soda Co. until June 27, 2012. He served as Vice Chairman of the North Metro Miracle League, an Atlanta-based charitable organization. He served as a Director of Color Imaging Incorporation since April 2003. He serves as a Director of Celtaxsys Inc. He served as a Director of Jones Soda Co. from August 30, 2006 to June 27, 2012. He is a Certified Public Accountant and graduated cum laude from Wake Forest University in 1991 with a Bachelor of Arts/B.S. degree in Accounting.

CEO Compensation
  • Rick's compensation has increased whilst company is loss making.
  • Rick's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Alimera Sciences management team in years:

1.3
Average Tenure
55
Average Age
  • The average tenure for the Alimera Sciences management team is less than 2 years, this suggests a new team.
Management Team

Dan Myers

TITLE
Non-Executive Chairman & Consultant
COMPENSATION
$1M
AGE
65
TENURE
1.3 yrs

Rick Eiswirth

TITLE
President
COMPENSATION
$831K
AGE
51
TENURE
1.3 yrs

Ken Green

TITLE
Consultant
COMPENSATION
$627K
AGE
61
TENURE
0.9 yrs

Dave Holland

TITLE
Co-Founder
COMPENSATION
$958K
AGE
55
TENURE
16.8 yrs

Phil Jones

TITLE
Chief Financial Officer
AGE
55
TENURE
1.3 yrs

Philip Ashman

TITLE
COO & Senior VP of Commercial Operations - Europe
COMPENSATION
$947K
AGE
54
TENURE
1.3 yrs

Christopher Visick

TITLE
VP, General Counsel & Secretary
TENURE
1.4 yrs

Sam Kaba

TITLE
Chief Medical Officer
AGE
57
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Alimera Sciences board of directors in years:

1.5
Average Tenure
54.5
Average Age
  • The average tenure for the Alimera Sciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rick Eiswirth

TITLE
President
COMPENSATION
$831K
AGE
51
TENURE
1.3 yrs

Peter Pizzo

TITLE
Independent Director
COMPENSATION
$78K
AGE
53
TENURE
10 yrs

Dan Myers

TITLE
Non-Executive Chairman & Consultant
COMPENSATION
$1M
AGE
65
TENURE
1.3 yrs

James Largent

TITLE
Lead Independent Director
COMPENSATION
$102K
AGE
69
TENURE
1.3 yrs

Garheng Kong

TITLE
Independent Director
COMPENSATION
$68K
AGE
44
TENURE
7.5 yrs

Brian Halak

TITLE
Independent Director
COMPENSATION
$68K
AGE
48
TENURE
16.3 yrs

Mary Szela

TITLE
Independent Director
COMPENSATION
$44K
AGE
56
TENURE
1.8 yrs

John Snisarenko

TITLE
Director
AGE
56
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Alimera Sciences individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
24. Jan 20 Buy Ronald Chez Individual 11. Dec 19 21. Jan 20 69,450 $9.74 $561,692
11. Dec 19 Buy Ronald Chez Individual 10. Oct 19 10. Dec 19 835,998 $0.22 $180,241
11. Dec 19 Buy J. Jones Individual 10. Dec 19 10. Dec 19 1,000 $9.29 $9,294
25. Nov 19 Buy John Snisarenko Individual 21. Nov 19 21. Nov 19 10,000 $4.95 $49,500
20. Nov 19 Buy James Largent Individual 19. Nov 19 19. Nov 19 3,000 $5.11 $15,344
19. Nov 19 Buy Richard Eiswirth Individual 14. Nov 19 14. Nov 19 6,667 $4.48 $29,890
X
Management checks
We assess Alimera Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alimera Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ALIM News

Simply Wall St News

Does The Alimera Sciences, Inc. (NASDAQ:ALIM) Share Price Fall With The Market?

Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market. … If this beta value holds true in the future, Alimera Sciences shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. … What this means for you: Since Alimera Sciences has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

The Alimera Sciences (NASDAQ:ALIM) Share Price Is Down 85% So Some Shareholders Are Rather Upset

In contrast to the share price, revenue has actually increased by 33% a year in the five year period. … A more detailed examination of the revenue and earnings may or may not explain why the share price languishes; there could be an opportunity. … A Different Perspective Alimera Sciences shareholders are down 24% for the year, but the market itself is up 6.4%.

Simply Wall St -

How Much Of Alimera Sciences, Inc. (NASDAQ:ALIM) Do Institutions Own?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … We also tend to see lower insider ownership in companies that were previously publicly owned. … With a market capitalization of US$60m, Alimera Sciences is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Should Alimera Sciences Inc (NASDAQ:ALIM) Be Your Next Stock Pick?

I've been keeping an eye on Alimera Sciences Inc (NASDAQ:ALIM) because I'm attracted to its fundamentals. … Looking at the company as a whole, as a potential stock investment, I believe ALIM has a lot to offer. … is a company with

Simply Wall St -

How Does Alimera Sciences Inc (NASDAQ:ALIM) Affect Your Portfolio Volatility?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

What Does Alimera Sciences Inc's (NASDAQ:ALIM) Ownership Structure Look Like?

I am going to take a deep dive into Alimera Sciences Inc’s (NASDAQ:ALIM) most recent ownership structure, not a frequent subject of discussion among individual investors. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Does Alimera Sciences Inc (NASDAQ:ALIM) Go Up With The Market?

If you are looking to invest in Alimera Sciences Inc’s (NASDAQ:ALIM), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … Generally, an investor should consider two types of risk that impact the market value of ALIM. … A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one.

Simply Wall St -

Alimera Sciences Inc's (NASDAQ:ALIM) Profit Outlook

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. … In this article, I will touch on the expectations for ALIM’s growth and when analysts expect the company to become profitable … View out our latest analysis for Alimera Sciences

Simply Wall St -

Loss-Making Alimera Sciences Inc (NASDAQ:ALIM) Expected To Breakeven

Alimera Sciences Inc's (NASDAQ:ALIM): Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. … Check out our latest analysis for Alimera Sciences ALIM is bordering on breakeven, according to analysts. … Next Steps: This article is not intended to be a comprehensive analysis on ALIM, so if you are interested in understanding the company at a deeper level, take a look at ALIM’s company page on Simply Wall St.

Simply Wall St -

Interested In Alimera Sciences Inc (ALIM)? Here's What Its Recent Track-Record Looks Like

Today I will run you through a basic sense check to gain perspective on how Alimera Sciences is doing by comparing its latest earnings with its long-term trend as well as the performance of its pharmaceuticals industry peers. … Check out our latest analysis for Alimera Sciences How Did ALIM's Recent Performance Stack Up Against Its Past? … For Alimera Sciences, the latest twelve-month earnings -$21M, which, relative to the prior year's figure, has become less negative.

Simply Wall St -

ALIM Company Info

Description

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Details
Name: Alimera Sciences, Inc.
ALIM
Exchange: NasdaqGM
Founded: 2003
$17,082,864
4,965,949
Website: http://www.alimerasciences.com
Address: Alimera Sciences, Inc.
6120 Windward Parkway,
Suite 290,
Alpharetta,
Georgia, 30005,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ALIM Common Stock Nasdaq Global Market US USD 22. Apr 2010
DB ASZ1 Common Stock Deutsche Boerse AG DE EUR 22. Apr 2010
Number of employees
Current staff
Staff numbers
125
Alimera Sciences employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 06:36
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/03/11
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.